Organization | Perkin Elmer Inc.

Perkin Elmer Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Waltham MA United States (1937)

Status: No NME R&D (1937)

Organization Overview

First Clinical Trial

2009

NCT00928213

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2014

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PerkinElmer, Inc.

Active Ingredients

Drugs in Phase 3 Trials (6)

Key: Perkin Elmer Inc. (2) Acquired (4)

cyclosporine (sandimmune) (3 trials)

difluprednate (durezol) (11 trials)

enoxaparin (lovenox) (1 trial)

hyaluronic acid (1 trial)

prednisone (meticorten) (1 trial)

progesterone (progestasert) (1 trial)

Drugs in Phase 2 Trials (1)

Key: Perkin Elmer Inc. (0) Acquired (1)

n-(4-hydroxyphenyl)all-trans retinamide (1 trial)

Drugs in Phase 1 Trials (12)

Key: Perkin Elmer Inc. (1) Acquired (11)

allogeneic cord blood (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

autologous umbilical cord blood (1 trial)

busulfan (Myleran) (1 trial)

clofarabine (clolar) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

melphalan (alkeran) (1 trial)

mycophenolate (CellCept) (1 trial)

rituximab (rituxan) (1 trial)

sargramostim (leukine) (1 trial)

tacrolimus (prograf) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Autism Spectrum Disorder (Phase 1)

Autistic Disorder (Phase 1)

Child Development Disorders, Pervasive (Phase 1)

Disease (Phase 1)

Pre-Eclampsia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 19
# of Trial APIs: 19